Genetic induction of phosphate toxicity significantly reduces the survival of hypercholesterolemic obese mice

Biochemical and Biophysical Research Communications

Volumn 415, Issue 3, 2011, Pages 434-438

  Ohnishi, Mutsuko ^a   Kato, Shigeko ^a   Razzaque, M Shawkat ^a  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Calcium; Longevity; Obese mice; Phosphate; Vitamin D

Indexed keywords

1 ALPHA HYDROXYLASE; CALCITRIOL; CALCIUM; CHOLESTEROL; OXYGENASE; PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL CALCIFICATION; BODY WEIGHT; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENETIC ENGINEERING; HYPERCHOLESTEROLEMIA; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; LIFESPAN; LIPID STORAGE; MOUSE; NONHUMAN; OBESITY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SOFT TISSUE INJURY; SURVIVAL RATE;

ANIMALS; CALCITRIOL; CALCIUM; CHOLESTEROL; GLUCURONIDASE; HYPERCHOLESTEROLEMIA; HYPERPHOSPHATEMIA; LEPTIN; MICE; MICE, KNOCKOUT; OBESITY; PHOSPHATES;

MUS;

EID: 82355180893     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.10.076     Document Type: Article

References (35)

1. Kato S., Nazneen A., Nakashima Y., Razzaque M.S., Nishino T., Furusu A., Yorioka N., Taguchi T. Pathological influence of obesity on renal structural changes in chronic kidney disease. Clin. Exp. Nephrol. 2009, 13:332-340.
2. Praga M., Morales E. Obesity, proteinuria and progression of renal failure. Curr. Opin. Nephrol. Hypertens. 2006, 15:481-486.
3. Liao J., Richards R., Zhang R., Reisin E. Effects of a modified low calorie diet in metabolic changes and kidney histology in young obese Zucker rats. J. Am. Soc. Nephrol. 2007, 18:823A.
4. Weisinger J.R., Kempson R.L., Eldridge L., Swenson R.S. The nephrotic syndrome: a complication of massive obesity. Ann. Intern. Med. 1974, 81:440-447.
5. Verani R.R. Obesity associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am. J. Kidney Dis. 1992, 20:629-634.
6. Warnke R.A., Kempson R.L. The nephrotic syndrome in massive obesity. A study by light, immunofluorescence and electron microscopy. Arch. Pathol. Lab. 1978, 102:431-438.
7. Pausova Z. From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr. Opin. Nephrol. Hypertens. 2006, 15:173-178.
8. Peralta C.A., Kurella M., Lo J.C., Chertow G.M. The metabolic syndrome and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2006, 15:361-365.
9. Tanaka M., Yamada S., Iwasaki Y., Sugishita T., Yonemoto S., Tsukamoto T., Fukui S., Takasu K., Muso E. Impact of obesity on IgA nephropathy: comparative ultrastructural study between obese and non-obese patients. Nephron Clin. Pract. 2009, 112:c71-c78.
10. Tsuboi N., Kawamura T., Ishii T., Hosoya T. Obesity-related nephropathy associated with a history of IgA nephropathy. Intern. Med. 2008, 47:1713-1718.
11. Potluri K., Hou S. Obesity in kidney transplant recipients and candidates. Am. J. Kidney Dis. 2010, 56:143-156.
12. Sampaio M.S., Reddy P.N., Kuo H.T., Poommipanit N., Cho Y.W., Shah T., Bunnapradist S. Obesity was associated with inferior outcomes in simultaneous pancreas kidney transplant. Transplantation 2010, 89:1117-1125.
13. Fukagawa M., Hamada Y., Nakanishi S., Tanaka M. The kidney and bone metabolism: nephrologists' point of view. J. Bone Miner. Metab. 2006, 24:434-438.
14. Razzaque M.S. Phosphate toxicity: new insights into an old problem. Clin. Sci. (Lond.) 2011, 120:91-97.
15. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., Ohyama Y., Kurabayashi M., Kaname T., Kume E., Iwasaki H., Iida A., Shiraki-Iida T., Nishikawa S., Nagai R., Nabeshima Y.I. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
16. Nakatani T., Bara S., Ohnishi M., Densmore M.J., Taguchi T., Goetz R., Mohammadi M., Lanske B., Razzaque M.S. In vivo genetic evidence of klotho-dependent functions of FGF23 in regulation of systemic phosphate homeostasis. FASEB J. 2009, 23:433-441.
17. Nakatani T., Ohnishi M., Razzaque M.S. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J. 2009, 23:3702-3711.
18. Ohnishi M., Nakatani T., Lanske B., Razzaque M.S. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int. 2009, 75:1166-1172.
19. Razzaque M.S., Sitara D., Taguchi T., St.-Arnaud R., Lanske B. Premature ageing-like phenotype in fibroblast growth factor 23 null mice is a vitamin-D mediated process. FASEB J. 2006, 20:720-722.
20. Tsujikawa H., Kurotaki Y., Fujimori T., Fukuda K., Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol. Endocrinol. 2003, 17:2393-2403.
21. Razzaque M.S. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat. Rev. Endocrinol. 2009, 5:611-619.
22. Razzaque M.S. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?. Am. J. Physiol. Renal Physiol. 2009, 296:F470-F476.
23. Ohnishi M., Kato S., Akiyoshi J., Atfi A., Razzaque M.S. Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions. FASEB J. 2011, 25:2031-2039.
24. Dardenne O., Prud'homme J., Arabian A., Glorieux F.H., St.-Arnaud R. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001, 142:3135-3141.
25. Zha Y., Le V.T., Higami Y., Shimokawa I., Taguchi T., Razzaque M.S. Life-long suppression of growth hormone-insulin-like growth factor I activity in genetically altered rats could prevent age-related renal damage. Endocrinology 2006, 147:5690-5698.
26. Razzaque M.S., Taguchi T. Collagen-binding heat shock protein (HSP) 47 expression in anti-thymocyte serum (ATS)-induced glomerulonephritis. J. Pathol. 1997, 183:24-29.
27. Ohnishi M., Nakatani T., Lanske B., Razzaque M.S. In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin D levels. Circ. Cardiovasc. Genet. 2009, 2:583-590.
28. Lanske B., Razzaque M.S. Premature aging in klotho mutant mice: cause or consequence?. Ageing Res. Rev. 2007, 6:73-79.
29. Sato A., Hirai T., Imura A., Kita N., Iwano A., Muro S., Nabeshima Y., Suki B., Mishima M. Morphological mechanism of the development of pulmonary emphysema in klotho mice. Proc. Natl. Acad. Sci. USA 2007, 104:2361-2365.
30. Razzaque M.S. The dualistic role of vitamin D in vascular calcifications. Kidney Int. 2011, 79:708-714.
31. Razzaque M.S. Osteo-renal regulation of systemic phosphate metabolism. IUBMB Life 2011, 63:240-247.
32. Ohnishi M., Razzaque M.S. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J. 2010, 24:3562-3571.
33. Fox C., Larson M., Leip E., Culleton B., Wilson P., Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004, 291:844-850.
34. Mathew A.V., Okada S., Sharma K. Obesity related kidney disease. Curr. Diabetes Rev. 2011, 7:41-49.
35. Speakman J.R., Westerterp K.R. Reverse epidemiology, obesity and mortality in chronic kidney disease: modelling mortality expectations using energetics. Blood Purif. 2010, 29:150-157.